Tumor infiltrating lymphocytes (TILs) have previously been identified as prognostic and predictive biomarkers in several cancers, including breast cancer. Despite these findings, assessment of TILs remains challenging, as existing methods are often subjective or semiquantitative, poorly reproducible, and cannot distinguish TIL subpopulations. Here, we develop and validate an objective immunofluorescence-based quantitative approach for measuring up to three TIL subpopulations per tissue section. The quantitative assay demonstrates improved reproducibility and similar specificity and sensitivity compared to traditional TIL classification.
Statement of Translational Relevance
Tumor infiltrating lymphocytes (TILs) have previously been identified as prognostic and predictive biomarkers in several cancers, including breast cancer. Despite these findings, assessment of TILs remains challenging, as existing methods are often subjective or semiquantitative, poorly reproducible, and cannot distinguish TIL subpopulations. Here, we develop and validate an objective immunofluorescence-based quantitative approach for measuring up to three TIL subpopulations per tissue section. The quantitative assay demonstrates improved reproducibility and similar specificity and sensitivity compared to traditional TIL classification.
We hope this initial report stimulates further validation of this objective method to determine its clinical utility in breast and other cancers.
Introduction
Neoadjuvant chemotherapy facilitates breast conserving surgery and enables early evaluation of response, allowing for discontinuation of ineffective treatment (1) . Moreover, patients who achieve pathologic complete response (pCR), elimination of invasive tumor following therapy, demonstrate better disease-free and overall survival (2, 3) . However, most patients do not achieve pCR when treated with standard neoadjuvant chemotherapy (4, 5) .
Tumor infiltrating lymphocytes (TILs) are an important immune component of the response to cancer (6) . Lymphocyte subpopulations are recognized by expression of specific cell surface biomarkers. CD3, a T-cell receptor protein, instigates a signaling cascade after antigen recognition to activate T cells (7) . CD8, a co-receptor for the T-cell receptor, recognizes the major histocompatibility I complex and is expressed on cytotoxic T lymphocytes, the predominant TIL subpopulation in breast cancer (8, 9) . CD20, a transmembrane protein expressed on B cells but not plasma cells, regulates B cell activity, proliferation, and differentiation (10, 11) . B cells drive the humoral, antibody-driven, immune response and often co-localize with T cells in tumors (11, 12) . Previously, lymphocyte infiltration has predicted improved response to chemotherapy and trastuzumab, and CD3, CD8, and CD20 have all been discussed as potential predictive biomarkers (13) (14) (15) (16) (17) (18) .
Assessing the predictive significance of TILs is challenging due to differing methods of measurement (19) . TIL measurement has been reported as TIL count (8, 20) , as density (TILs per high powered field) (13, 18) , in semi-quantitative scales (21, 22) , and as percentage of stromal infiltrate (14, 23) . TIL location is also not assessed in a standardized manner. Locations can be defined as intratumoral or stromal, which is further subdivided into adjacent and distant stroma (13) . Another concern is variable selection of and number of fields of view analyzed, especially considering TIL heterogeneity (18) . Perhaps the most significant issue plaguing TIL quantification is subjectivity and non-reproducibility. Several assays attempt to objectively quantify TILs, but many consider only one biomarker, precluding relationships between TIL subpopulations (24) (25) (26) (27) (28) . Moreover, these assays are often challenging on large cohorts, where they are unable to account for location, and measure TILs semi-quantitatively.
This study aims to objectively measure TILs on a cohort of biopsies obtained before neoadjuvant chemotherapy. We develop and validate an immunofluorescence-based quantitative approach for measuring CD3, CD8, and CD20 expression within the stroma adjacent to the tumor. We objectively analyze expression in all fields of view, determine which TIL biomarkers predict pathological complete response, and compare their predictive value.
Materials and Methods

Tissue Collection and Patient Cohort
Freshly resected tonsil tissue was collected from four patients who underwent tonsillectomies at Yale-New Haven Hospital in 2013. Upon collection, each tonsil specimen was divided into two approximately equal halves. One half was formalin fixed for 24-48 hours before paraffin embedding. The other half was placed in RPMI media on ice for single cell suspension preparation.
Paraffin embedded pre-therapeutic core biopsies were collected from 105 consecutive invasive breast cancer patients that received neoadjuvant therapy, primarily anthracycline and taxane-based, as described previously (29). The distribution of treatment regimens, nuclear grade, tumor size, hormone receptor status, and HER2 status is described in Table 1. HER2   status was determined by IHC, with 0 and 1+ classified as HER2 negative and 3+ as HER2 positive. Cases that were HER2 2+ were tested by FISH and then classified into positive or negative groups as per the 2013 ASCO/CAP guidelines. Tissue was used after written patient consent. The study was performed according to the Yale University Institutional Review Boards protocol #9505008219.
Flow Cytometry
Single cell suspensions were extracted from tonsil tissue and filtered through a 70-μm nylon strainer (Corning). The resulting suspension was centrifuged and reconstituted to 10 Sorter Core Facility, and data was collected using FACSDiva software. Flow cytometry plots were generated and analyzed with FLOWJO software (Tree Star).
Pathologic Assessment of TILs
Research. Histopathologic analysis was performed on hematoxylin and eosin-stained sections of 103 core biopsies from the cohort. Sections when available were obtained from archives or otherwise stained prior to reading. Analysis was conducted by two pathologists (V.B. and C.N.), both blinded to clinical parameters and response. TILs were quantified as percentage estimate of the tumor stroma area that contained lymphocytic infiltrate (14) . Percentages were reported in increments of 10 percent, with greater than 50 percent infiltrate denoted as lymphocyte predominant breast cancer (LPBC) (23) .
Multiplexed Immunofluorescence Staining for TILs
In situ detection of CD3, CD8, and CD20 with cytokeratin and DAPI were conducted on the same slide (Supplemental Figure 1) . Briefly, slides were deparaffinized and rehydrated before pH8 EDTA antigen retrieval. Endogenous peroxidase activity was blocked with dual endogenous peroxidase block (Dako) and non-specific antigens were blocked with 0.3% bovine serum albumin in Tris-buffered saline/Tween. Primary monoclonal antibodies against CD3
(1:100, Novus, Rabbit IgG Clone NB600-1441), CD8 (1:250, Dako, Mouse IgG1 Clone C8/144B), and CD20 (1:150, Dako, Mouse IgG2a Clone L26) were co-incubated for 1 hour at room temperature. Slides were incubated sequentially with three HRP-conjugated secondary antibodies for one hour at room temperature prior to tyramide-based HRP activation for 10 minutes, followed by 1mM benzoic hydrazide with 0.15% hydrogen peroxide to quench HRP activation. The secondary antibodies were anti-rabbit Envision reagent (Dako), anti-mouse IgG1 For analysis with AQUA software, staining artifact and FOVs without invasive breast carcinoma were manually removed. A total compartment, consisting of all nuclei, and a tumor mask were generated by dichotomizing DAPI signal and CD3 signal, respectively, so that each pixel was "on" or "off." The stromal compartment excluded the tumor mask from the total compartment. AQUA scores were calculated by dividing the summated pixel intensity within each compartment by area. Only cases with three or more cytokeratin positive FOVs were included.
Statistical Analysis
A weighted kappa test assessed interobserver variability between pathologist estimates.
Pearson's correlation coefficient (R) compared AQUA scores within different compartments.
ANOVA testing was used for comparison of AQUA scores to histopathologic assessment and clinicopathologic characteristics and for analysis of response, and log-rank P values are reported. Logistic regression was used for univariate and multivariate analyses, with the CD3, CD8, and CD20 AQUA scores analyzed on a continuous scale. To generate a ratio of the likelihood of pCR for high TIL populations compared to low TIL populations, AQUA scores were split into low and high populations at a cutpoint objectively determined by Joinpoint software (NCI Surveillance Research). All statistical analysis was performed using Statview software (SAS Institute) and QuickCalcs (GraphPad Software).
Results
Histopathologic TIL Assessment
Two pathologists estimated TIL infiltration in the tumor stroma on hematoxylin and eosin stained slides (H&E TILs) for 93 cases ( Figure 1A-C) . TIL infiltrate was reported in increments of 10% with fair interobserver variability (weighted κ = 0.393) ( Figure 1D ). 8 patients (8.6%) exhibited lymphocyte predominant breast cancer (LPBC) with moderate interobserver variability of LPBC vs. non-LPBC (κ = 0.501). Of the patients with LPBC, 5 (62.5%) achieved pCR. TIL percentages between pathologists were averaged for further analysis, and H&E TILs were significantly higher in the patients who achieved pCR compared to those who did not achieve pCR (p = 0.0075, Figure 1E ).
Validation of Quantitative Immunofluorescence of CD3, CD8, and CD20
Four tonsil specimens were analyzed for CD3, CD8, and CD20 expression by both 
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Of 93 slides analyzed, 87 had sufficient FOVs for analysis, ranging from 4 to 118 (mean 33.5, median 27). Stromal AQUA scores were averaged across all FOVs for each case.
Correlation between AQUA scores within the stromal and total compartments for CD3, CD8, and CD20 was very strong and better than between tumor mask and total compartment AQUA scores, especially for CD20 (Supplemental Figure 2) . Index breast tissue microarrays stained alongside the cohort were reproducible on serial sections for all markers (Supplemental Figure   3 ).
Analysis of each FOV allows visualization of intratumoral heterogeneity. Some FOVs had minimal TILs ( Figure 3A) , whereas others had moderate TILs with low expression ( Figure   3B ) or numerous TILs ( Figure 3C ). Heat maps were constructed to visualize this intratumoral heterogeneity ( Figure 3D ).
Association of TILs with Clinicopathologic Characteristics
Research. 
Next, TIL subpopulations were compared with standard breast cancer classifiers including ER, PR, HER2, and triple negative status. CD20 AQUA score was significantly higher (p = 0.0051), and CD8 expression trended higher in ER negative patients. CD3 (p = 0.0301), CD8 (p = 0.0168) and CD20 (p = 0.0145) expression were also significantly higher in PR negative tumors. No markers were significantly correlated with HER2, although CD3 stromal expression trended higher with HER2 positivity. Although only 24 patients (27.6%) had tumors negative for ER, PR, and HER2, CD8 (p = 0.0052) and CD20 (p = 0.0058) stromal expression were significantly higher in triple negative tumors (Supplemental Figure 4) .
Association of TILs with Response to Neoadjuvant Chemotherapy
To dichotomize TILs to assess relationship with response, cutpoints between high and low expression of all four markers were determined by generating three possible Joinpoints (32) and selecting the middle cutpoint (Supplemental Figure 5) . Cutpoints for CD3, CD8, and CD20
were above the median AQUA score, and the rate of pCR above the cutpoint was 41.9% for CD3, CD8, and CD20 scores ( Table 2 ). Multivariable analysis with patient age, tumor size, nodal metastases, ER, PR, and HER2 positivity, and Ki-67 AQUA score from a previous study Receiver operating characteristic curves were generated to assess the sensitivity and specificity of CD3, CD8, and CD20 AQUA score and H&E TILs for predicting pCR. The most sensitive and specific marker was CD20 (AUC 0.685) whereas CD3 (AUC 0.626), CD8 (AUC 0.653), and H&E TILs (AUC 0.672) were somewhat less sensitive and specific (Supplemental Figure 6 ).
Analysis Stratified by Molecular Subtype
Association of CD3, CD8, and CD20 expression with pCR was stratified by ER, HER2, and triple negative status. High CD8 expression trended with pCR among ER negative patients, and increased CD20 AQUA score was significantly predictive (p = 0.0015) among ER positive patients. Higher CD8 (p = 0.0005) and CD20 (p = 0.0021) expression predicted pCR among HER2 negative cases, whereas higher CD20 expression also predicted pCR (p = 0.0386) among HER2 positive patients. Among triple negative patients, increased CD8 expression significantly predicted pCR (p = 0.0386), whereas higher CD3 and CD20 expression trended with pCR (Supplemental Figure 7) . This is the first study to significantly correlate CD20 expression with response to neoadjuvant chemotherapy in both univariate and multivariate analysis. Previously, this association has been equivocal. Although one study demonstrated this correlation in univariate analysis (14) , another study demonstrated no significant association and that genetic T cell markers but not B cell markers predicted chemotherapeutic response (17) . This discrepancy could be attributed to localization of CD20 positive lymphocytes. In this study, CD20 expressing lymphocytes were often clustered in a few FOVs and therefore could be easily missed in tissue microarrays with minimal stroma. In another study, B cell deficient mice were capable of an immune response, whereas T cell deficient mice were not (33) . Although that study antigen presentation to T cells (11) . The increased sensitivity and specificity of CD20 compared to CD3 and CD8 in our study supports an important role for B cells in response to chemotherapy.
Since our study is relatively small, we look forward to future studies to validate this result.
Flow cytometry is commonly used to quantify and characterize lymphocytes and cytokines in several diseases including cancer (12, 34, 35) Moreover, the in situ assay does not require a cell suspension, where dispase and collagenase could disrupt cell surface biomarker expression (36, 37). In our quantitative assay, lymphocyte quantification by immunofluorescence-based multiplexing and flow cytometry was concordant.
While not perfect, minor differences could be attributable to tissue processing, including formalin fixation. Interestingly, this variability was minimized in samples with more FOVs.
Recently, an international group led by J. Galon proposed an "Immunoscore" that utilizes immune infiltration to develop a quantitative assay with prognostic and predictive power, feasibility, inexpensiveness, robustness, reproducibility, and standardization (19) . Their 
producing a discrete score from I0 to I4 (24) . This effort is notable but is specifically designed for colon cancer. Breast cancer is a unique disease and similar efforts are underway in breast cancer. In contrast, the method proposed here has advantages over traditional methods and the Galon "Immunoscore" in that our assay reports lymphocyte infiltration as continuous data.
Moreover, our assay analyzes three TIL biomarkers and addresses the contribution of each lymphocyte subpopulation to prognostic and predictive studies. Future studies will be necessary to assess the generality of our assay including assessment in multi-institutional trials and across quantitative platforms.
This work has a number of limitations. Perhaps most significant is the relatively small size of the cohort and non-uniform patient treatment. Future larger studies are required to validate these results prior to introduction into the clinic. A second and also significant limitation is the fact that this score is dependent on a quantitative immunofluorescent platform.
While many institutions have these platforms, they are almost exclusively in the research domain. However, at least two commercial CLIA labs now provide patient data to clinicians based on quantitative immunofluorescence. We are optimistic that the increased reproducibility and the increased objectivity of the data will lead to increased popularity and adoption of these approaches. Another limitation is that TIL quantification is not reported as a traditional percentage, but rather an AQUA score. This score represents intensity divided by the area, thus simulating a concentration. Since our method measures activation markers of T and B cells, concentration may be relatively more representative than percentage. However, further data is required to verify this assertion.
In summary, we have developed an objective immunofluorescence-based assay for detecting and quantifying TILs in situ. This method measures CD3, CD8, and CD20 expression on one slide and reflects the location and heterogeneity of different lymphocyte subpopulations.
We successfully validated this assay by comparison to flow cytometry on tonsil tissue and compared it to pathologist TIL estimates. We demonstrated that CD3, CD8, and CD20 predict pCR following neoadjuvant chemotherapy, with CD20 as the most sensitive and specific marker.
We believe this method offers potential advantages over existing lymphocyte quantification methods, including objectivity and reproducibility. However, future use at multiple institutions in a range of clinical settings will be required to determine its true value.
